Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer

Study summary

The purpose of this study is to evaluate the anti-tumor efficacy of daraxonrasib monotherapy in patients with unresectable or advanced/metastatic, KRAS-mutant BTC who have progressed on or are intolerant of 1st line systemic therapy.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedDaraxonrasib

The study team can explain what participation involves.

Who it may be forKRAS · Early-stage or resectable · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 28, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Not Yet Recruiting

The study is not accepting participants yet.

What kind of study?Phase 2

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 2
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Interventions being studied: Drug: Daraxonrasib

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting

Early-stage or resectable→Metastatic or stage IV→Recurrent or relapsed→

Biomarkers

KRAS→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Unresectable locally advanced or metastatic histologically or cytologically confirmed biliary tract cancer
Must have documented disease progression or intolerance of one prior systemic chemotherapy regimen (with or without immunotherapy) for unresectable and/or advanced stage disease.
Age ≥ 18 years
Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.
Have measurable disease based on RECIST 1.1.
Documented KRAS mutation
Adequate organ and marrow function defined by study-specified laboratory tests and procedures.
Willingness to provide serial tissue and blood samples for mandatory translational research.
Evidence of post-menopausal status or a negative pregnancy test in women of childbearing potential (WOCBP).
All participants must agree to use acceptable form of birth control while on study.
Ability to take oral medications and willingness to keep daily adherence record in a medication diary.
Must understand the study regimen, its requirements, risks and discomforts and is able and willing to sign the informed consent form in accordance with regulatory and institutional guidelines.

Reasons someone may not be able to joinExclusion criteria

Any systemic anti-cancer therapy for advanced BTC within 3 weeks of enrollment or 5 half-lives of the drug, whichever is shorter.
Prior treatment with any KRAS, RTK, or MEK inhibitor or other RAS-pathway targeting signal transduction inhibitor agents
Major surgery, extended field radiotherapy, or local regional therapy within 4 weeks from first dose of study drug, limited field radiotherapy within 2 weeks of first dose, or failure to recover from side effects of these prior therapies
Known additional malignancy that is progressing and requires active treatment.
Receiving concomitant medications that interfere with Daraxonrasib.
Significant cardiovascular disease.
Significant cardiac conduction abnormalities.
Impaired gastrointestinal function.
Active autoimmune disease
Clinically active ascites.
Active uncontrolled infection requiring systemic therapy within 72 hours prior to C1D1.
Known history of human immunodeficiency virus (HIV).
Active or chronic hepatitis B or hepatitis C.
Known history of central nervous system (CNS) metastases and/or history of uncontrolled seizures.
Any uncontrolled acute or chronic medical illness.
History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
Pregnant or breastfeeding
Patient is unwilling or unable to follow the study schedule for any reason.
Has known psychiatric or substance use disorder that would interfere with cooperation with the requirements of the trial.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Sidney Kimmel Comprehensive Cancer CenterBaltimore, Maryland

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 28, 2026. Always confirm current availability with the study team.

View original record ↗